420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
Adi Diab(Cleveland Clinic), Michael E. Hurwitz(Yale University), Karl D. Lewis(University of Colorado Denver), Jonathan Zalevsky(Nektar Therapeutics (United States)), Erika Puente-Poushnejad(Nektar Therapeutics (United States)), Michele Maio(University of Siena), Brendan D. Curti(Providence Portland Medical Center), Gregory A. Daniels(University of California San Diego), Ute Hoch(University of Arizona), Alexander I. Spira(Virginia Cancer Specialists), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Shanhong Guan(Nektar Therapeutics (United States)), Mary Tagliaferri(Nektar Therapeutics (United States)), Ewa Kalinka‐Warzocha(Apple (Israel)), Daniel Cho(Madigan Army Medical Center), Wei Lin(Nektar Therapeutics (United States)), Sue Currie(St. Paul's Hospital), Tuan Nguyen(Nektar Therapeutics (United States)), Scott S. Tykodi(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Sekwon Jang(Virginia Cancer Institute), Mario Sznol(Yale University)
Cited by 7
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k